Insmed’s (NASDAQ:INSM) Buy Rating Reaffirmed at Cowen
Insmed (NASDAQ:INSM)‘s stock had its “buy” rating reaffirmed by equities researchers at Cowen in a research note issued to investors on Monday, January 6th, AnalystRatings.com reports. They currently have a $56.00 price target on the biopharmaceutical company’s stock. Cowen’s price target points to a potential upside of 125.17% from the stock’s previous close.
Other analysts have also recently issued reports about the company. Morgan Stanley set a $37.00 price target on Insmed and gave the stock a “buy” rating in a research report on Friday, November 1st. Credit Suisse Group restated an “outperform” rating and issued a $40.00 price objective on shares of Insmed in a report on Thursday, January 2nd. Canaccord Genuity assumed coverage on shares of Insmed in a report on Thursday, January 2 ...